Taken together, our findings have provided new insights on the role of OSM-OSMR signaling in promoting cisplatin resistance in ovarian cancer and opportunities to reverse cisplatin-resistant mechanisms in ovarian cancer through targeting anti-OSMR antibodies. The gene discussed is OSM; the disease is ovarian carcinoma.